Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells.
Fujiwara R, Taniguchi Y, Rai S, Iwata Y, Fujii A, Fujimoto K, Kumode T, Serizawa K, Morita Y, Espinoza JL, Tanaka H, Hanamoto H, Matsumura I. Fujiwara R, et al. Among authors: hanamoto h. Biochem Biophys Res Commun. 2022 Oct 20;626:156-166. doi: 10.1016/j.bbrc.2022.08.010. Epub 2022 Aug 10. Biochem Biophys Res Commun. 2022. PMID: 35994825
Influence of Epstein-Barr virus infection in adult T-cell leukemia.
Ueda S, Maeda Y, Yamaguchi T, Hanamoto H, Hijikata Y, Tanaka M, Takai S, Hirase C, Morita Y, Kanamaru A. Ueda S, et al. Among authors: hanamoto h. Hematology. 2008 Jun;13(3):154-62. doi: 10.1179/102453308X316130. Hematology. 2008. PMID: 18702873 Free article.
Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms.
Taniguchi Y, Tanaka H, Luis EJ, Sakai K, Kumode T, Sano K, Serizawa K, Rai S, Morita Y, Hanamoto H, Tsubaki K, Nishio K, Matsumura I. Taniguchi Y, et al. Among authors: hanamoto h. Int J Hematol. 2017 Nov;106(5):691-703. doi: 10.1007/s12185-017-2302-5. Epub 2017 Aug 5. Int J Hematol. 2017. PMID: 28780601 Clinical Trial.
Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.
Morita Y, Maeda Y, Yamaguchi T, Urase F, Kawata S, Hanamoto H, Tsubaki K, Ishikawa J, Shibayama H, Matsumura I, Matsuda M. Morita Y, et al. Among authors: hanamoto h. Cancer Sci. 2018 Oct;109(10):3209-3215. doi: 10.1111/cas.13739. Epub 2018 Aug 26. Cancer Sci. 2018. PMID: 30007103 Free PMC article. Clinical Trial.
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis.
Takakuwa T, Yamamura R, Ohta K, Kaneko H, Imada K, Nakaya A, Fuchida SI, Shibayama H, Matsuda M, Shimazu Y, Adachi Y, Kosugi S, Uchiyama H, Tanaka H, Hanamoto H, Shimura Y, Kanda J, Onda Y, Uoshima N, Yagi H, Yoshihara S, Hino M, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S. Takakuwa T, et al. Among authors: hanamoto h. Eur J Haematol. 2021 Apr;106(4):555-562. doi: 10.1111/ejh.13586. Epub 2021 Jan 31. Eur J Haematol. 2021. PMID: 33476404
Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial.
Rai S, Inoue H, Hanamoto H, Matsuda M, Maeda Y, Wada Y, Haeno T, Watatani Y, Kumode T, Hirase C, Espinoza JL, Morita Y, Tanaka H, Tatsumi Y, Matsumura I. Rai S, et al. Among authors: hanamoto h. Int J Hematol. 2021 Aug;114(2):205-216. doi: 10.1007/s12185-021-03148-0. Epub 2021 Apr 17. Int J Hematol. 2021. PMID: 33864623
Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.
Rai S, Inoue H, Sakai K, Hanamoto H, Matsuda M, Maeda Y, Haeno T, Watatani Y, Kumode T, Serizawa K, Taniguchi Y, Hirase C, Espinoza JL, Morita Y, Tanaka H, Ashida T, Tatsumi Y, Nishio K, Matsumura I. Rai S, et al. Among authors: hanamoto h. Cancer Sci. 2022 Feb;113(2):660-673. doi: 10.1111/cas.15224. Epub 2021 Dec 5. Cancer Sci. 2022. PMID: 34837284 Free PMC article.
Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis.
Onda Y, Kanda J, Kaneko H, Shimura Y, Fuchida SI, Nakaya A, Itou T, Yamamura R, Tanaka H, Shibayama H, Shimazu Y, Uchiyama H, Yoshihara S, Adachi Y, Matsuda M, Hanamoto H, Uoshima N, Kosugi S, Ohta K, Yagi H, Kanakura Y, Matsumura I, Hino M, Nomura S, Shimazaki C, Takaori-Kondo A, Kuroda J; Kansai Myeloma Forum. Onda Y, et al. Among authors: hanamoto h. Ther Adv Hematol. 2022 Jun 24;13:20406207221104584. doi: 10.1177/20406207221104584. eCollection 2022. Ther Adv Hematol. 2022. PMID: 35785245 Free PMC article.
ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial.
Morita Y, Nannya Y, Ichikawa M, Hanamoto H, Shibayama H, Maeda Y, Hata T, Miyamoto T, Kawabata H, Takeuchi K, Tanaka H, Kishimoto J, Miyano S, Matsumura I, Ogawa S, Akashi K, Kanakura Y, Mitani K. Morita Y, et al. Among authors: hanamoto h. Int J Hematol. 2022 Nov;116(5):659-668. doi: 10.1007/s12185-022-03414-9. Epub 2022 Jul 12. Int J Hematol. 2022. PMID: 35821550 Free PMC article.
81 results